EASL临床实践指南:原发性胆汁性胆管炎的诊断与管理
该指南总结了原发性胆汁性胆管炎(PBC)的诊断与管理证据,强调基于胆汁淤积性肝酶和抗线粒体抗体诊断、风险分层及个体化终身管理,治疗目标为预防终末期肝病和改善症状,现有药物包括熊去氧胆酸、奥贝胆酸及超说明书用药。
要点
- 诊断通常基于胆汁淤积性肝炎的血清肝酶指标及循环抗线粒体抗体。
- 风险分层对确保患者获得个体化诊疗至关重要。
- 治疗目标为预防终末期肝病和改善相关症状。
核心结论
- 指南强调对PBC患者采取结构化、终身且个体化的诊疗方法,并提供了帮助临床医生诊断和有效管理患者的框架。
研究设计与样本
- 由EASL制定的临床实践指南,总结了PBC诊断与管理的证据。
主要发现
- PBC是一种慢性炎症性自身免疫性胆汁淤积性肝病,未经治疗将进展为终末期胆汁性肝硬化。
- 患者表现和病程多样,风险分层对确保个体化诊疗很重要。
- 治疗目标为预防终末期肝病和改善相关症状。
关键数值与推荐
- 诊断通常基于胆汁淤积性肝炎的血清肝酶指标及循环抗线粒体抗体。
- 药物治疗包括获批药物(熊去氧胆酸和奥贝胆酸)及超说明书药物(纤维酸衍生物、布地奈德)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Primary biliary cholangitis (PBC) is a chronic inflammatory autoimmune cholestatic liver disease, which when untreated will culminate in end-stage biliary cirrhosis. Diagnosis is usually based on the presence of serum liver tests indicative of a cholestatic hepatitis in association with circulating antimitochondrial antibodies. Patient presentation and course can be diverse and risk stratification is important to ensure all patients receive a personalised approach to their care. The goals of treatment and management are the prevention of end-stage liver disease, and the amelioration of associated symptoms. Pharmacologic approaches in practice, to reduce the impact of the progressive nature of disease, currently include licensed therapies (ursodeoxycholic acid and obeticholic acid) and off-label therapies (fibric acid derivatives, budesonide). These clinical practice guidelines summarise the evidence for the importance of a structured, life-long and individualised, approach to the care of patients with PBC, providing a framework to help clinicians diagnose and effectively manage patients.
引用
- EASL Clinical Practice Guidelines: The diagnosis and management of patients with primary biliary cholangitis. J Hepatol. 2017. PMID: 28427765. doi:10.1016/j.jhep.2017.03.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。